{"nctId":"NCT00384176","briefTitle":"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX","startDateStruct":{"date":"2006-08-30","type":"ACTUAL"},"conditions":["Colorectal Cancer"],"count":1814,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bevacizumab","Drug: 5-fluorouracil ( in FOLFOX)","Drug: Leucovorin (in FOLFOX)","Drug: Oxaliplatin (in FOLFOX)"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Cediranib","Drug: 5-fluorouracil ( in FOLFOX)","Drug: Leucovorin (in FOLFOX)","Drug: Oxaliplatin (in FOLFOX)"]}],"interventions":[{"name":"Cediranib","otherNames":["RECENTIN™","AZD2171"]},{"name":"Bevacizumab","otherNames":["Avastin®"]},{"name":"5-fluorouracil ( in FOLFOX)","otherNames":["5-FU"]},{"name":"Leucovorin (in FOLFOX)","otherNames":[]},{"name":"Oxaliplatin (in FOLFOX)","otherNames":["Eloxatin®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical Diagnosis of colon or rectal cancer\n* No prior systemic therapy for metastatic disease. Any adjuvant/neoadjuvant oxaliplatin therapy must have been received \\>12 months prior to study entry and adjuvant/neoadjuvant 5-FU must have been received \\>6 months prior to study entry.\n\nExclusion Criteria:\n\n* Prior treatment with a VEGF Inhibitor, including bevacizumab and cediranib.\n* Poorly controlled hypertension","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival","description":"Progression is defined as the number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Number of months from randomisation to the date of death from any cause","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.8","spread":null},{"groupId":"OG001","value":"21.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate","description":"Objective response rate is Complete Response (CR) + Partial Response (PR) as defined below:\n\nCR = Disappearance of all target lesions. PR = At least a 30% decrease in the sum of longest diameters (LDs) of target lesions, taking as reference the baseline sum of LDs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"328","spread":null},{"groupId":"OG001","value":"337","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Duration of Response is calculated as the time from the first recording of CR/PR until the patient progresses, regardless of whether the patient was still taking study medication. Only confirmed responses are included in the calculation. For patients who had not progressed, the end date used in the calculation of duration of response is the data cut-off date of 15th November 2009.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"9.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Tumour Size","description":"Percentage change in tumour size from baseline to first RECIST assessment (Week 8) ((Week 8 - baseline)/baseline)\\*100","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.2","spread":"21.8"},{"groupId":"OG001","value":"-22.1","spread":"19.55"}]}]}]},{"type":"SECONDARY","title":"Time to Worsening of Health Related Quality of Life (QOL) Based on the FACT Colorectal Symptom Index (FCSI)","description":"Time to worsening of symptoms, as measured by the FACT colorectal symptom index (FCSI), will be defined as the time when a sustained clinically important deterioration in the total score from the FCSI has been recorded.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"170","spread":null},{"groupId":"OG001","value":"245","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":275,"n":705},"commonTop":["Diarrhoea","Nausea","Fatigue","Neutropenia","Hypertension"]}}}